Aligos Therapeutics Inc.
ALGS | NASDAQ
$5.57
+$0.08 (+1.46%)
Sep 22, 2026, 9:30 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.19M | 3.95M | 15.53M | 13.91M | 4.36M | n/a |
Cost of Revenue | 930K | n/a | n/a | n/a | n/a | 3.33M |
Gross Profit | 1.26M | 3.95M | 15.53M | 13.91M | 4.36M | -3.33M |
Operating Income | -87.99M | -89.15M | -88.13M | -97.58M | -128.32M | -97.83M |
Interest Income | 2.16M | 1.67M | 1.24M | 1.64M | 132K | 1.26M |
Pretax Income | -23.88M | -130.88M | -86.88M | -95.94M | -128.19M | -108.38M |
Net Income | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M | -108.54M |
Selling & General & Admin | 20.72M | 22.83M | 30.62M | 26.41M | 28.53M | 14.62M |
Research & Development | 69.45M | 70.27M | 73.04M | 85.08M | 104.15M | 79.89M |
Other Expenses | -930K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 89.24M | 93.1M | 103.66M | 111.49M | 132.68M | 94.51M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 10.55M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 90.17M | 93.1M | 103.66M | 111.49M | 132.68M | 97.83M |
Income Tax Expense | 314K | 331K | 795K | 106K | 143K | 161K |
Shares Outstanding (Basic) | 9.88M | 6.26M | 24.87M | 42.7M | 39.86M | 34.18M |
Shares Outstanding (Diluted) | 9.88M | 6.26M | 24.87M | 42.7M | 39.86M | 34.18M |
EPS (Basic) | -2.45 | -20.94 | -3.52 | -2.25 | -3.22 | -3.18 |
EPS (Diluted) | -2.45 | -20.94 | -3.52 | -2.25 | -3.22 | -3.18 |
EBITDA | -22.95M | -128.26M | -83.82M | -92.27M | -124.41M | -105.06M |
EBIT | -23.88M | -130.88M | -86.88M | -95.94M | -128.19M | -108.38M |
Depreciation & Amortization | 930K | 2.62M | 3.07M | 3.68M | 3.78M | 3.33M |
Add to Watchlist
Select watchlists to add or remove ALGS